SCHEMBL4619173

SCHEMBL4619173

CCc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)N1CCN(CC(=O)N2CCCC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.54
SFRP1 Q8N474 4/20 0.50
WNT3 P56703 3/20 0.49
POLB P06746 1/20 0.47
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 8/20 0.46
GAA P10253 2/20 0.46
PKM P14618 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 1/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4617917 0.88 ALDH1A1 (0.60) L3MBTL1SFRP1WNT3POLBNPC1
SCHEMBL4617036 0.85 SFRP1 (0.64) L3MBTL1SFRP1POLBALDH1A1SMN1; SMN2
SCHEMBL4616470 0.80 ALDH1A1 (0.63) L3MBTL1SFRP1POLBALDH1A1GAA
SCHEMBL4618864 0.78 SFRP1 (0.53) L3MBTL1SFRP1POLBALDH1A1GAA
SCHEMBL4616150 0.77 ALDH1A1 (0.59) L3MBTL1SFRP1POLBALDH1A1GAA
SCHEMBL4617911 0.72 ALDH1A1 (0.72) L3MBTL1SFRP1ALDH1A1SMN1; SMN2HTT
SCHEMBL3243254 0.71 L3MBTL1 (0.61) L3MBTL1POLBALDH1A1SMN1; SMN2TSHR
SCHEMBL5248869 0.71 L3MBTL1 (0.75) L3MBTL1POLBNPC1ALDH1A1GAA
SCHEMBL13972864 0.70 L3MBTL1 (0.58) L3MBTL1POLBNPC1ALDH1A1
SCHEMBL13959166 0.69 L3MBTL1 (0.57) L3MBTL1POLBNPC1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 L3MBTL1 4156/4885SFRP1 1/4885WNT3 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.